Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The MENA ethosuximide market size is expected to grow at a CAGR of 3.30% between 2024 and 2032. The market is being driven by the increasing prevalence of epilepsy and growing healthcare infrastructure and expenditure.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Ethosuximide is an anticonvulsant drug which is used to regulate absence (petit mal) seizures in epileptic patients. The compound is obtained from succinic acid and operates by reducing instances of abnormal electrical activity in the patient’s brain. In absence seizures, the patient experiences a short loss of awareness during which there is lack of response but may continue to blink eyes or stare.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on product, the market is segmented into capsule, tablet, and syrup, among others. On the basis of procurement, the market is classified into annual procurement (government agencies, public hospitals) and private procurement (drug stores, private hospitals). By country, the market for ethosuximide in MENA is divided into Saudi Arabia, United Arab Emirates, Iran, Egypt, Morocco, Qatar, Kuwait, and Oman, among others.
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the MENA ethosuximide market, covering their competitive landscape and latest developments like mergers, acquisitions, investments and expansion plans.
The capsule segment, based on formulation, accounts for a healthy share of the MENA ethosuximide market due to its ability to be combined with other components that can help in the treatment. A capsule can contain ethosuximide along with polyethylene glycol, gelatin, and sorbitol, among other ingredients useful for treating epilepsy. Ethosuximide capsules are capable of suppressing the paroxysmal three cycle per second spike which comes along with lapses of consciousness during absence seizures. Meanwhile, the syrup segment is expected to witness a positive growth in the forecast period, owing to the faster rate of absorption, greater optimisation, easy digestibility, and suitability for children.
Based on procurement, private procurement (drug stores, private hospitals) segment occupies a growing share of the MENA ethosuximide market due to the rapidly improving private healthcare network in the region. As absence seizures are relatively lesser known and can be difficult to notice and diagnose, potential patients are likelier to belong to higher income groups and visit private hospitals where the quality of treatment is considered to be higher. Although the hospital infrastructure varies significantly between the different countries in the region, efforts to encourage private participation in the healthcare sector, to improve the quality of care while reducing burden on the government, can be witnessed throughout the region.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Pfizer Ltd is a leading pharmaceutical company which produces research-based pharmaceutical and biopharmaceutical products. It is also one of the leading manufacturers of vaccines, catering to the treatment demands of various chronic conditions, by innovating to develop new products and formulations. The company was established in the year 1952 and is headquartered in Tadworth, United Kingdom.
Essential Pharma Ltd produces and ensures sustainable supply of low-volume clinically-superior, and well established pharmaceutical products. The company strives to help patients get access to good quality therapeutics and medicines that can help them manage their healthcare concerns. The company was founded in the year 2011 and is currently headquartered in Surrey, United Kingdom.
Qatar Pharmaceuticals Industries is a pharmaceutical company which manufactures and sells generic and branded drugs aimed towards improving the health of patients suffering from chronic conditions. The product portfolio of this company includes softgels, liquids, tablets, and capsules, among others. Qatar Pharmaceuticals Industries was founded in 2008 and is headquartered in Doha, Qatar.
Other market players include Delta Pharma, among others.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Formulation |
|
Breakup by Procurement |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market is estimated to grow at a CAGR of 3.20% between 2024 and 2032.
The rapid growth of the healthcare sector across the emerging economies of MENA, increasing prevalence of absence seizures in the region, and growing standards of living are the major drivers of the market.
The key trends in the market include the growing research and development activities aimed at improving the quality of epilepsy medications and increasing incorporation of modern technology in diagnostic and treatment procedures.
Capsule, tablet, and syrup, among others, are the different formulation in the market.
Annual procurement (government agencies, public hospitals) and private procurement (drug stores, private hospitals) are the various procurements of ethosuximide in the market.
Saudi Arabia, United Arab Emirates, Iran, Egypt, Morocco, Qatar, Kuwait, and Oman, among others, are the different countries in the ethosuximide market in MENA.
Ethosuximide is used for treating absence (petit mal) seizures in patients that have epilepsy.
Potential side effects of ethosuximide can include upset stomach, diarrhoea, loss of appetite, drowsiness, and dizziness.
Pfizer Ltd, Essential Pharma Ltd, Qatar Pharmaceuticals Industries, and Delta Pharma, among others, are the key players of the MENA ethosuximide market, according to the report.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share